Agilon Health stock falls 27% after CEO resignation, earnings guidance withdrawal.

• Agilon health, inc. faces investigation for securities law violations. • CEO and Board Director Steven Sell stepped down on August 4, 2025. • Shares fell 27% after Company withdrew full year 2025 earnings guidance. • DJS Law Group investigates claims on behalf of investors.

Agilon Health Inc. (NYSE: AGL) is facing a securities law investigation after the company announced the resignation of its President, CEO, and Board Director, Steven Sell, on August 4, 2025. The investigation, led by the DJS Law Group, focuses on whether Agilon issued misleading statements or failed to disclose pertinent information to investors [1].

Following the announcement, Agilon's shares fell by more than 27% in after-hours trading. The company also withdrew its full-year 2025 earnings guidance, citing leadership changes and market uncertainties [2]. This withdrawal came after Agilon reported its second-quarter 2025 earnings, which missed analyst estimates and resulted in a significant drop in revenue and a substantial increase in net loss [3].

The company's medical margin, which measures the difference between revenue and expenses, swung from a $106 million profit in the same quarter last year to a $53 million loss. This reversal was driven by reductions in expected revenue, contributing to a deeper net loss and a significant drop in adjusted EBITDA [4].

Agilon's stock has been extremely volatile, with 79 moves greater than 5% over the last year. The recent decline has brought the stock to $0.80 per share, down 87.6% from its 52-week high of $6.46 [3].

Investors who bought shares at the IPO in April 2021 would now see their investment worth $25.81, a significant decline from the initial investment value [3]. The company has suspended its full-year 2025 guidance, citing ongoing leadership transitions and market dynamics [4].

The DJS Law Group, known for its expertise in securities class actions and corporate governance litigation, is investigating claims on behalf of Agilon's investors. The firm specializes in enhancing investor returns through balanced counseling and aggressive advocacy [1].

References:
[1] https://www.prnewswire.com/news-releases/agilon-health-inc-investigated-for-securities-fraud-violations---contact-the-djs-law-group-to-discuss-your-rights--agl-302527166.html
[2] https://www.marketscreener.com/news/agilon-health-inc-investigated-for-securities-fraud-violations-contact-the-djs-law-group-to-disc-ce7c5ed3de8ff325
[3] https://finance.yahoo.com/news/why-agilon-health-agl-stock-164121733.html
[4] https://ih.advfn.com/market-news/article/14072/agilon-health-shares-plunge-after-q2-miss-leadership-shakeup-and-suspended-guidance